NEW YORK (GenomeWeb) – OpGen reported after the close of the market on Wednesday that its first quarter earnings fell 30 percent, driven by a sharp drop in laboratory services revenues.

For the three months ended March 31, the firm's revenues fell to $771,771 from $1.1 million in Q1 2016.

Product sales fell 22 percent to $734,502 from $947,219 a year ago, while laboratory services revenues fell 88 percent to $16,105 from $129,420. The company also recorded $21,164 in revenues from collaborations in Q1 2017.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Hundreds of scientists have signed a letter criticizing the open-access Plan S, ScienceInsider reports.

NPR speaks with Rep. Eddie Bernice Johnson (D-Texas) about the US House of Representatives science committee.

A start-up company aiming to match cancer patients to treatments closes after about six weeks, Stat News reports.

In PLOS this week: somatic mutation associations unearthed in thousands of cancer exomes, pathogen detection assay, and more.